Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $523000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 11.21% year-over-year to $523000.0, compared with a TTM value of $2.3 million through Dec 2025, down 8.0%, and an annual FY2025 reading of $2.3 million, down 8.0% over the prior year.
  • Depreciation & Amortization (CF) was $523000.0 for Q4 2025 at Heron Therapeutics, down from $615000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $794000.0 in Q4 2021 and bottomed at $523000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $680500.0, with a median of $711000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) grew 19.0% in 2021, then fell 20.08% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $794000.0 in 2021, then dropped by 0.38% to $791000.0 in 2022, then dropped by 9.48% to $716000.0 in 2023, then fell by 17.74% to $589000.0 in 2024, then fell by 11.21% to $523000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for HRTX at $523000.0 in Q4 2025, $615000.0 in Q3 2025, and $611000.0 in Q2 2025.